

David M Hockenbery

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11125114/publications.pdf>

Version: 2024-02-01

49
papers

6,433
citations

172207

29
h-index

223531

46
g-index

51
all docs

51
docs citations

51
times ranked

6863
citing authors

#	ARTICLE	IF	CITATIONS
1	Bcl-2 functions in an antioxidant pathway to prevent apoptosis. <i>Cell</i> , 1993, 75, 241-251.	13.5	3,396
2	Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3. <i>Nature Cell Biology</i> , 2001, 3, 183-191.	4.6	436
3	Mitochondrial Proliferation and Paradoxical Membrane Depolarization during Terminal Differentiation and Apoptosis in a Human Colon Carcinoma Cell Line. <i>Journal of Cell Biology</i> , 1997, 138, 449-469.	2.3	287
4	Bcl-2 family proteins as regulators of oxidative stress. <i>Seminars in Cancer Biology</i> , 2009, 19, 42-49.	4.3	152
5	bcl-2, a novel regulator of cell death. <i>BioEssays</i> , 1995, 17, 631-638.	1.2	126
6	Hsp90 Inhibition Decreases Mitochondrial Protein Turnover. <i>PLoS ONE</i> , 2007, 2, e1066.	1.1	126
7	A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells. <i>Cell</i> , 2014, 157, 1644-1656.	13.5	118
8	A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. <i>Blood</i> , 2007, 109, 4557-4563.	0.6	115
9	The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. <i>Cell Cycle</i> , 2008, 7, 1054-1066.	1.3	112
10	Gastrointestinal Graft-versus-Host Disease in Recipients of Autologous Hematopoietic Stem Cells: Incidence, Risk Factors, and Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 226-234.	2.0	92
11	Targeting mitochondria for cancer therapy. <i>Environmental and Molecular Mutagenesis</i> , 2010, 51, 476-489.	0.9	92
12	BCL-XL Dimerization by Three-dimensional Domain Swapping. <i>Journal of Molecular Biology</i> , 2006, 356, 367-381.	2.0	89
13	Fnip1 regulates skeletal muscle fiber type specification, fatigue resistance, and susceptibility to muscular dystrophy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 424-429.	3.3	87
14	Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: A randomized, controlled trial. <i>Gastroenterology</i> , 1998, 115, 28-35.	0.6	81
15	Biophysical Characterization of Recombinant Human Bcl-2 and Its Interactions with an Inhibitory Ligand, Antimycin A. <i>Biochemistry</i> , 2001, 40, 4911-4922.	1.2	81
16	Bcl-XL Mutations Suppress Cellular Sensitivity to Antimycin A. <i>Journal of Biological Chemistry</i> , 2004, 279, 2159-2165.	1.6	68
17	PERSISTENT NAUSEA AND ANOREXIA AFTER MARROW TRANSPLANTATION. <i>Transplantation</i> , 1998, 66, 1319-1324.	0.5	68
18	Computationally designed high specificity inhibitors delineate the roles of BCL2 family proteins in cancer. <i>ELife</i> , 2016, 5, .	2.8	65

#	ARTICLE	IF	CITATIONS
19	Disruption of Fnip1 Reveals a Metabolic Checkpoint Controlling B Lymphocyte Development. <i>Immunity</i> , 2012, 36, 769-781.	6.6	64
20	Conditional Disruption of Raptor Reveals an Essential Role for mTORC1 in B Cell Development, Survival, and Metabolism. <i>Journal of Immunology</i> , 2016, 197, 2250-2260.	0.4	60
21	BCL-2, a novel regulator of apoptosis. , 1996, 60, 12-17.		52
22	Mitochondria and apoptosis: New therapeutic targets. <i>Advances in Cancer Research</i> , 2002, 85, 203-242.	1.9	48
23	Promises and challenges of targeting Bcl-2 anti-apoptotic proteins for cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2004, 1705, 43-51.	3.3	48
24	Severe Gastrointestinal Bleeding After Hematopoietic Cell Transplantation, 1987â€“1997: Incidence, Causes, and Outcome. <i>American Journal of Gastroenterology</i> , 2001, 96, 385-393.	0.2	47
25	BCL-2 and BCL-XL Restrict Lineage Choice during Hematopoietic Differentiation. <i>Journal of Biological Chemistry</i> , 2003, 278, 25158-25165.	1.6	45
26	2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 2073-2080.	1.9	43
27	A mitochondrial Achilles' heel in cancer?. <i>Cancer Cell</i> , 2002, 2, 1-2.	7.7	39
28	Caspase-3 and inhibitor of apoptosis protein(s) interactions in <i>Saccharomyces cerevisiae</i> and mammalian cells. <i>FEBS Letters</i> , 2000, 481, 13-18.	1.3	38
29	Targeting BCL-2-related proteins in cancer therapy. <i>Cancer Biology and Therapy</i> , 2003, 2, S105-14.	1.5	37
30	Suppression of p53 function in normal human mammary epithelial cells increases sensitivity to extracellular matrixâ€“induced apoptosis. <i>Journal of Cell Biology</i> , 2001, 155, 471-486.	2.3	32
31	Pan-cancer transcriptional signatures predictive of oncogenic mutations reveal that Fbw7 regulates cancer cell oxidative metabolism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 5462-5467.	3.3	31
32	ORAL BECLOMETHASONE DIPROPIONATE FOR TREATMENT OF HUMAN INTESTINAL GRAFT-VERSUS-HOST DISEASE. <i>Transplantation</i> , 1995, 60, 1231-1238.	0.5	30
33	Lymphocytic gastritis resembling graft-vs.-host disease following autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 1998, 4, 43-48.	2.0	28
34	Fibrosing Cholestatic Hepatitis C After Hematopoietic Cell Transplantation. <i>American Journal of Surgical Pathology</i> , 2015, 39, 212-220.	2.1	26
35	A novel approach for monitoring extracellular acidification rates: based on bead injection spectrophotometry and the lab-on-valve system Electronic supplementary information (ESI) available: Derivation of eqn. (4). See http://www.rsc.org/suppdata/an/b3/b315007k/ . <i>Analyst</i> , The, 2004, 129, 205.	1.7	25
36	Caspase-3 inhibits growth in <i>Saccharomyces cerevisiae</i> without causing cell death. <i>FEBS Letters</i> , 1999, 446, 9-14.	1.3	24

#	ARTICLE	IF	CITATIONS
37	Inhibition of vaccinia virus replication by nitazoxanide. <i>Virology</i> , 2018, 518, 398-405.	1.1	23
38	Loss of Fnip1 alters kidney developmental transcriptional program and synergizes with TSC1 loss to promote mTORC1 activation and renal cyst formation. <i>PLoS ONE</i> , 2018, 13, e0197973.	1.1	18
39	Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF- α and TRAIL-initiated apoptotic signals. <i>Experimental Hematology</i> , 2008, 36, 1660-1672.	0.2	17
40	Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. <i>Leukemia and Lymphoma</i> , 2007, 48, 1003-1014.	0.6	16
41	Preclinical pharmacology of 2-methoxyantimycin A compounds as novel antitumor agents. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 291-298.	1.1	14
42	BCL-xL overexpression effectively protects against tetrafluoroethylcysteine-induced intramitochondrial damage and cell death. <i>Biochemical Pharmacology</i> , 2005, 69, 147-157.	2.0	12
43	MMPs in Unusual Places. <i>American Journal of Pathology</i> , 2006, 169, 1101-1103.	1.9	8
44	Targeted therapies for epithelial cancers: In vivo efficacy of the BCL-2/BCL-XL inhibitor 2-MeAA. <i>Cancer Biology and Therapy</i> , 2007, 6, 465-466.	1.5	3
45	Bak to Basics of Colonocyte Renewal. <i>Gastroenterology</i> , 2009, 136, 763-766.	0.6	3
46	The Warburg Effect and Beyond: Metabolic Dependencies for Cancer Cells. , 2013, , 35-51.		3
47	Oral beclomethasone dipropionate in gastrointestinal graft-versus-host disease. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 695-700.	1.3	1
48	ORAL BECLOMETHASONE DIPROPIONATE FOR TREATMENT OF HUMAN INTESTINAL GRAFT-VERSUS-HOST DISEASE. <i>Transplantation</i> , 1995, 60, 1231-1238.	0.5	1
49	Proliferative mitochondrial dysfunction and apoptosis. <i>Advances in Cell Aging and Gerontology</i> , 2001, 5, 123-140.	0.1	0